Plus Therapeutics Inc PSTV

Healthcare Biotechnology

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.

NDAQ:PSTV - Post by User

Plus Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by coolfooldumbguyon Sep 23, 2019 2:10pm

115 Views

Post# 30155606

it's a buy today for me using DCA

by dollar cost averaging,and by loading up big time with this one,my target price for it is $16 per share,and my costs are $5.00 per share,and still waiting for more beaten down cheap shares.

<< Previous

Bullboard Posts

Next >>

This profitable gold stock is on its way up